⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13941281 | 1.00 | — | — | |
| SCHEMBL105725 | 1.00 | — | — | |
| SCHEMBL15513617 | 0.79 | — | — | |
| SCHEMBL17300369 | 0.79 | — | — | |
| SCHEMBL28234932 | 0.77 | ADH1B (0.53) | — | |
| SCHEMBL2437966 | 0.75 | — | — | |
| SCHEMBL2437965 | 0.75 | — | — | |
| SCHEMBL19462820 | 0.74 | — | — | |
| SCHEMBL25180 | 0.74 | — | — | |
| SCHEMBL13074302 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670166-B2 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-06-06 | — | — | US | disclosed |
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-20140088303-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2014-03-27 | — | — | US | disclosed |
| US-8624024-B2 | Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-01-07 | — | — | US | disclosed |
| US-20120214988-A1 | PHOSPHORAMIDE COMPOUND, METHOD FOR PRODUCING THE SAME, LIGAND, COMPLEX, CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL | SEKISUI MEDICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7129059-B2 | Process for the preparation of compounds with enhanced optical purity | DSM IP ASSETS B.V. (NL) | 2006-10-31 | — | — | US | disclosed |
| US-20060127997-A1 | Process for the preparation of compounds with enhanced optical purity | QUAEDFLIEG PETER J L | 2006-06-15 | — | — | US | disclosed |
| EP-1141333-B1 | PROCESS FOR THE ENZYMATIC PREPARATION OF AMINO ACID DERIVATIVES WITH ENHANCED OPTICAL PURITY | DSM IP ASSETS BV (NL) | 2006-06-14 | — | — | EP | disclosed |
| US-7018817-B1 | Process for the preparation of compounds with enhanced optical purity | DSM IP ASSETS B.V. (NL) | 2006-03-28 | — | — | US | disclosed |
| EP-1013769-A1 | Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity | DSM N.V. (NL) | 2000-06-28 | — | — | EP | disclosed |